06.01.02
Ephedra Study Published
A six-month, randomized, placebo-controlled clinical trial on ephedra, conducted by Columbia and Harvard universities (Boozer et al.) and published in April’s issue of the International Journal of Obesity, reaffirms the findings of a December 2000 comprehensive science-based risk assessment performed by Cantox Health Sciences International. The Cantox Report on Ephedra concluded that ephedra is safe, under recommended conditions of use, at a total daily dosage of 90 mg, divided into smaller doses of up to 30 mg.
A six-month, randomized, placebo-controlled clinical trial on ephedra, conducted by Columbia and Harvard universities (Boozer et al.) and published in April’s issue of the International Journal of Obesity, reaffirms the findings of a December 2000 comprehensive science-based risk assessment performed by Cantox Health Sciences International. The Cantox Report on Ephedra concluded that ephedra is safe, under recommended conditions of use, at a total daily dosage of 90 mg, divided into smaller doses of up to 30 mg.